C. King

发表

Synthesis and structure-activity relationships of novel arylpiperazines as potent and selective agonists of the melanocortin subtype-4 receptor.

T. I. Richardson, P. Ornstein, K. Briner, 2004, Journal of medicinal chemistry.

[20] Purification of farnesylpyrophosphate synthetase by affinity chromatography

C. King, C. Poulter, D. L. Bartlett, 1985 .

Efficacy and Safety of Nemonoxacin versus Levofloxacin for Community-Acquired Pneumonia

R. Perng, C. King, Yu-Ting Chang, 2010, Antimicrobial Agents and Chemotherapy.

Efﬁcacy and Safety of Nemonoxacin versus Levoﬂoxacin for Community-Acquired Pneumonia (cid:1)

R. Perng, C. King, Yu-Ting Chang, 2010 .

Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.

R. Campbell, D. Clawson, C. King, 2006, Journal of medicinal chemistry.

Syntheses of Steroidal Vinyl Ethers Using Palladium Acetate−Phenanthroline as Catalyst

C. King, P. Weintraub, 1997 .

Castanospermine-glucosides as selective disaccharidase inhibitors.

C. King, P. S. Liu, K. M. Robinson, 1990, Biochemical pharmacology.

Comparative In Vitro Activities of Nemonoxacin (TG-873870), a Novel Nonfluorinated Quinolone, and Other Quinolones against Clinical Isolates

C. King, Hua-Chien Chen, T. Lauderdale, 2010, Antimicrobial Agents and Chemotherapy.

Synthesis of enantiomerically pure (+)- and (-)-18-methoxycoronaridine hydrochloride and their preliminary assessment as anti-addictive agents.

S. D. Glick, R. J. Herr, C. King, 2000, Bioorganic & medicinal chemistry letters.

A facile, practical synthesis of 2,6-dideoxy-2,6-imino-7-O-.beta.-D-glucopyranosyl-D-glycero-L-gulo-heptitol (MDL 25,637)

C. King, P. Anzeveno, L. J. Creemer, 1989 .

Model studies of terpene biosynthesis. Stereospecific cyclization of N-methyl-(S)-4-([1'-2H]neryloxy)pyridinium methyl sulfate to .alpha.-terpineol

C. King, C. Poulter, 1982 .

Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.

R. Campbell, D. Clawson, C. King, 2008, Journal of medicinal chemistry.

Synthesis of Castanospermine Glucosides

C. King, Paul S. Liu, 1992 .

Model studies of terpene biosynthesis. A stepwise mechanism for cyclization of nerol to .alpha.-terpineol

C. King, C. Poulter, 1982 .

Immobilization of substrates in enzyme-catalyzed hydrolysis

C. King, A. Margolin, 1993 .

In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.

C. King, P. Hsueh, Yen-Hsu Chen, 2009, The Journal of antimicrobial chemotherapy.

Castanospermine-glucosides are potent, selective, long-acting sucrase inhibitors.

C. King, P. S. Liu, K. M. Robinson, 1989, Journal of Pharmacology and Experimental Therapeutics.

Regiocontrolled C-8 Acylation of Castanospermine

C. King, L. Paquette, Hon-Chung Tsui, 1996 .

Antibody responses to in vitro translation products following albendazole therapy for Echinococcus granulosus

C. King, R. Blanton, G. Okelo, 1991, Antimicrobial Agents and Chemotherapy.

Multiple-Dose Safety, Tolerability, and Pharmacokinetics of Oral Nemonoxacin (TG-873870) in Healthy Volunteers

C. King, Yu-Ting Chang, Shu-Jen Chen, 2010, Antimicrobial Agents and Chemotherapy.

Syntheses of Steroidal Vinyl Ethers Using Palladium Acetate- Phenanthroline as Catalyst.

C. King, P. Weintraub, 1997 .

Efficient Preparation of the 18-Methoxycoronaridine Side-Chain Precursor

C. King, Matthew P. Rainka, M. Dowling, 2006 .

TG-0054, a Novel and Potent Stem Cell Mobilizer, Displays Excellent PK/PD and Safety Profile in Phase I Trial.

C. King, Li-wen Chang, Ying-Huey Huang, 2009 .